mRNA Vaccine for Advanced Lung Cancer and Pulmonary Metastases of Solid Tumors

BMD006 is an off-the-shelf antitumor mRNA vaccine targeting lung cancer and lung metastatic solid tumors. This is a single-center, open-label, dose-escalation clinical trial. The study aims to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of BMD006 in patients with advanced lung cancer or advanced solid tumors with lung metastasis who have progressed on or are ineligible for standard therapeutic options. This trial also further explores the clinical efficacy of BMD006 in combination with Immuno-Oncology (IO) therapy.

Trial Details

NCT ID
NCT06928922
Phase
EARLY_PHASE1
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • BMD006 monotreatment
  • BMD006 in combination with PD-1 antibody
  • BMD006 in combination with PD-1/VEGF antibody
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Able to understand and comply with the requirements of the study protocol, voluntarily participate in the trial, and sign a written informed consen…
  • Must be at least 18 (inclusive) at the time of signing the ICF, and both male and female participants are eligible.
  • Histologically or cytologically confirmed as advanced lung cancer (driver gene negative) or advanced solid tumors with lung metastasis, and having …
  • Agree to provide fresh tumor tissue samples or archived tumor tissue samples within the past three years.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →